Lead Product(s) : JZP898
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : JZP898
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 30, 2022
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2022
Lead Product(s) : Mocravimod,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mocravimod (also known as KRP203), is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. This novel investigational drug has been assessed in Phase 1 and Phase 2 trials for safety and tolerability, as well as for efficacy in several autoimmu...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : Mocravimod,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emactuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Healthcaps India
Deal Size : $45.0 million
Deal Type : Series A Financing
SynOx Therapeutics raises €37M in Series A Financing
Details : The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 19, 2020
Lead Product(s) : Emactuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Healthcaps India
Deal Size : $45.0 million
Deal Type : Series A Financing
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 03, 2019
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 30, 2019
PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2018
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 14, 2018
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 08, 2016